PL1996292T3 - Zastosowanie peptydów do kontroli obrażeń popromiennych - Google Patents

Zastosowanie peptydów do kontroli obrażeń popromiennych

Info

Publication number
PL1996292T3
PL1996292T3 PL07715910T PL07715910T PL1996292T3 PL 1996292 T3 PL1996292 T3 PL 1996292T3 PL 07715910 T PL07715910 T PL 07715910T PL 07715910 T PL07715910 T PL 07715910T PL 1996292 T3 PL1996292 T3 PL 1996292T3
Authority
PL
Poland
Prior art keywords
peptides
control
radiation injury
injury
radiation
Prior art date
Application number
PL07715910T
Other languages
English (en)
Inventor
Robbert Benner
Nisar Ahmed Khan
Richard Michael Carlton
Original Assignee
Biotempt Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt Bv filed Critical Biotempt Bv
Publication of PL1996292T3 publication Critical patent/PL1996292T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL07715910T 2006-03-07 2007-03-06 Zastosowanie peptydów do kontroli obrażeń popromiennych PL1996292T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77989606P 2006-03-07 2006-03-07
US81187806P 2006-06-07 2006-06-07
EP06076181A EP1864692A1 (en) 2006-06-07 2006-06-07 Use of peptides for the control of radiation injury
PCT/NL2007/050092 WO2007102735A1 (en) 2006-03-07 2007-03-06 Use of peptides for the control of radiation injury
EP07715910A EP1996292B1 (en) 2006-03-07 2007-03-06 Use of peptides for the control of radiation injury

Publications (1)

Publication Number Publication Date
PL1996292T3 true PL1996292T3 (pl) 2013-04-30

Family

ID=37192586

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07715910T PL1996292T3 (pl) 2006-03-07 2007-03-06 Zastosowanie peptydów do kontroli obrażeń popromiennych

Country Status (10)

Country Link
US (4) US7795226B2 (pl)
EP (2) EP1864692A1 (pl)
KR (1) KR101478320B1 (pl)
AU (1) AU2007222178B2 (pl)
CA (1) CA2645550C (pl)
DK (1) DK1996292T3 (pl)
ES (1) ES2399276T3 (pl)
NZ (1) NZ570996A (pl)
PL (1) PL1996292T3 (pl)
WO (1) WO2007102735A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US9895413B2 (en) 2002-11-13 2018-02-20 Board Of Regents, University Of Texas System Protection against and treatment of ionizing radiation
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
AU2009212143A1 (en) 2008-02-07 2009-08-13 Terapio Corporation Compositions for delivery of cargo such as drugs proteins and/or genetic materials
EP3087996A1 (en) * 2009-07-24 2016-11-02 Terapio Corporation Compositions and methods of use for post-radiation protection
US8672126B2 (en) * 2010-01-06 2014-03-18 Apple Inc. Foldable case for use with an electronic device
KR101758424B1 (ko) 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
WO2012149263A1 (en) * 2011-04-29 2012-11-01 Thomas Jefferson University Treatment and prevention of gastrointestinal syndrome
KR101969199B1 (ko) 2013-03-11 2019-04-15 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 폐 기능의 개선 및 방사선 유발된 폐 합병증의 예방 및/또는 치료를 위한 물질 및 방법
WO2014145906A2 (en) 2013-03-15 2014-09-18 Phd Preventative Health Care And Diagnostics, Inc. A prefilled medication device, method of making and using the same
US9669070B2 (en) * 2013-09-17 2017-06-06 The Feinstein Institute For Medical Research Treatment and prevention of radiation injury using MFG-E8
US9649353B2 (en) 2013-09-17 2017-05-16 Terapio Corporation Methods of preventing or treating mucositis by administering RLIP76
EP3065827A4 (en) * 2013-11-04 2017-05-24 Sloan-Kettering Institute for Cancer Research Hematopoietic recovery from radiation injury
US10743909B2 (en) 2014-04-03 2020-08-18 Corbin Clinical Resources, Llc Transperineal prostate biopsy device, systems, and methods of use
US10064681B2 (en) 2014-04-03 2018-09-04 Corbin Clinical Resources, Llc Method, system, and device for planning and performing, guided and free-handed transperineal prostate biopsies
US12144519B2 (en) 2014-04-03 2024-11-19 Corbin Clinical Resources, Llc Transperineal prostate biopsy and treatment methods
WO2016054458A1 (en) 2014-10-02 2016-04-07 Cytosorbents Corporation Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
EP3459540A1 (en) 2014-11-24 2019-03-27 Entrinsic Health Solutions, Inc. Amino acid compositions for the treatment of symptoms of disease
EP3522882A4 (en) 2016-10-04 2020-06-24 The University of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND USES THEREOF
CN108484738B (zh) * 2018-03-28 2022-03-15 中国人民解放军军事科学院军事医学研究院 辐抗肽突变蛋白及其制备与纯化方法
WO2019236453A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy
EP3996694A1 (en) * 2019-07-31 2022-05-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptides as inhibitors of fibrotic matrix accumulation
US11349294B2 (en) * 2020-01-29 2022-05-31 Eaton Intelligent Power Limited Solid state circuit interrupter
AU2021251123A1 (en) * 2020-04-06 2022-10-20 Corbin Clinical Resources, Llc Transperineal prostate biopsy and treatment methods
US12109327B2 (en) 2020-08-20 2024-10-08 King Abdullah University Of Science And Technology Scaffolds from self-assembling tetrapeptides support 3D spreading, osteogenic differentiation and angiogenesis of mesenchymal stem cells
US12590121B2 (en) 2020-08-20 2026-03-31 King Abdullah University Of Science And Technology Peptide compound with repetitive sequences
US12116421B2 (en) 2020-09-02 2024-10-15 King Abdullah University Of Science And Technology Peptide-based Dopa containing adhesive gels
KR20230079126A (ko) 2020-09-30 2023-06-05 바이오템프트, 비.브이. 혈관 투과성 문제를 해결하는 자가포식-저해성 펩타이드 및 이의 유기산 염
WO2022107089A1 (en) 2020-11-23 2022-05-27 King Adbullah University Of Science And Technology Developing lateral flow immunochromatography (lfia) peptide-based test strips for rapid detection of antigens and antibodies against specific antigens
CN115169103A (zh) * 2022-06-30 2022-10-11 哈尔滨工业大学 一种太阳能电池辐照损伤的模拟计算方法

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3855397A (en) 1973-04-12 1974-12-17 Allied Chem Method of producing sodium carbonate and bicarbonate spherules from brine
US3898328A (en) * 1973-12-03 1975-08-05 Syntex Inc Dry stable composition for the treatment of scours and dehydration
DE2360794C2 (de) * 1973-12-06 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von Peptiden
IL44774A (en) * 1974-05-06 1977-07-31 Baron E Pharmaceutical composition containing acetyl salicyclic acid
GB1518364A (en) * 1976-05-05 1978-07-19 Beecham Group Ltd Pharmaceutical composition
GB1524740A (en) * 1976-11-09 1978-09-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions for use in the suppression of gastric reflux
US4108846A (en) * 1977-02-01 1978-08-22 Hoffmann-La Roche Inc. Solid phase synthesis with base N alpha-protecting group cleavage
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS5822474B2 (ja) 1980-06-10 1983-05-09 天野製薬株式会社 コレシストキニン・パンクレオザイミンc端ペプチドアミドスルフエ−トエステルの製造法
US4351762A (en) 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US4571336A (en) * 1983-08-25 1986-02-18 Endorphin, Inc. Immune stimulation
US4977244A (en) * 1985-06-27 1990-12-11 The United States Of America As Represented By The Department Of Health And Human Services Uromodulin and a process of purifying it
US4651762A (en) * 1985-07-01 1987-03-24 Bowden Industries, Inc. Agitation parts degreaser
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
AU600724B2 (en) 1986-05-12 1990-08-23 Boehringer Ingelheim International Gmbh Novel combination
GB2194866A (en) 1986-07-14 1988-03-16 British Broadcasting Corp Timing signals
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
US5002961A (en) * 1987-10-19 1991-03-26 Merrell Dow Pharmaceuticals Method for reducing injury with imidazol-2-thionecarboxamides
US4966848A (en) 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
ATE136551T1 (de) * 1988-05-10 1996-04-15 Alpha 1 Biomedicals Inc Festphase-verfahren zur gewinnung von thymosin- alpha-1
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5175254A (en) 1988-09-24 1992-12-29 Societe D'expansion Scientifque Expansia Solid phase peptide synthesis using a polyacrylic support in aqueous solution
US5308834A (en) 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US6309822B1 (en) 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
US5102393A (en) * 1989-07-17 1992-04-07 Survival Technology, Inc. Autoinjector converted from intramuscular to subcutaneous mode of injection
US5223421A (en) 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
US5070187A (en) 1989-11-03 1991-12-03 Trustees Of Boston University Pharmacologically effective antagonists of arginine-vasopressin
US6051596A (en) * 1990-08-10 2000-04-18 Anormed, Inc. Immunosuppressive compositions
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US5200507A (en) * 1991-04-12 1993-04-06 Mallinckrodt Specialty Chemicals Company Method of separating a peptide from a resin
JPH06508029A (ja) 1991-05-17 1994-09-14 カイロン コーポレイション NF−↓kB転写活性化物質のインヒビター及びその使用
US5223397A (en) * 1991-06-05 1993-06-29 Sangstat Medical Corporation Soluble hla cross-match
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
PT633929E (pt) * 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
ATE152734T1 (de) * 1992-05-30 1997-05-15 Sikiric Predrag Bpc-peptide, deren herstellung und verwendung
US5436270A (en) 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
FR2706772A1 (en) 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US5380668A (en) * 1993-07-06 1995-01-10 University Of Utah Research Foundation Compounds having the antigenicity of hCG
AU7476894A (en) * 1993-07-29 1995-02-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5837478A (en) 1993-12-23 1998-11-17 Icos Corporation Method of identifying modulators of binding between and VCAM-1
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5677275A (en) * 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
GB2293100A (en) * 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
US5700781A (en) 1994-10-04 1997-12-23 Harris; Pamela Jo Method for treating Kaposi's sarcoma and HIV infections
US5851997A (en) * 1994-10-04 1998-12-22 Harris; Pamela Jo Use of human chorionic gonadotropin as an immune-potentiating antiviral agent
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
AU5289596A (en) * 1995-04-13 1996-10-30 Chugai Seiyaku Kabushiki Kaisha Peptide suppressing ixbalpha phosphorylation
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5942494A (en) * 1995-10-06 1999-08-24 The Trustees Of Columbia University In The City Of New York Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
JP2860637B2 (ja) * 1995-12-11 1999-02-24 末綱 陽子 新規なペプチドおよび活性化酸素阻害剤
JP2835504B2 (ja) * 1995-12-11 1998-12-14 末綱 陽子 新規なペプチドおよび活性化酸素阻害剤
JPH09176187A (ja) * 1995-12-27 1997-07-08 Kagaku Gijutsucho Hoshasen Igaku Sogo Kenkyusho 活性酸素消去能を有するヒスチジン含有ペプチド
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6361992B1 (en) * 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
CA2180786C (en) 1996-07-02 2008-05-27 David Lightfoot Plants containing the gdha gene and methods of use thereof
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
GB9617021D0 (en) 1996-08-13 1996-09-25 Salpep Biotechnology Inc Novel peptides for treatment of inflammation and shock
US6361922B1 (en) * 1996-10-16 2002-03-26 Eastman Kodak Company Thicker optical recording layers comprising a tetra dye having a metallized azo dianionic dye with cationic dye counterions
GB9624927D0 (en) 1996-11-29 1997-01-15 Oxford Glycosciences Uk Ltd Gels and their use
US5966712A (en) 1996-12-12 1999-10-12 Incyte Pharmaceuticals, Inc. Database and system for storing, comparing and displaying genomic information
JP2001511649A (ja) 1997-02-07 2001-08-14 トーマス・ジェファーソン・ユニバーシティ サイトカインレセプターガンマ鎖のペプチド模倣物
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
US6416959B1 (en) 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
DE69837118T2 (de) 1997-04-07 2007-12-27 Fisher Biolmage Aps Ein Verfahren zum Screenen von Substanzen hinsichtlich ihres Effekts auf cAMP Spiegel basierend auf intrazellulärer Translokation von PKA
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6583109B1 (en) * 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2314397C (en) 1997-12-12 2010-04-13 University Of Western Ontario Novel peptide, apoep1.b, compositions and uses thereof
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6022696A (en) 1998-04-02 2000-02-08 Washington State University Research Foundation Methods of identifying agonists or antagonists of angiotensin IV
US20090042807A1 (en) * 1998-05-20 2009-02-12 Nisar Ahmed Khan Oligopeptide treatment of ischemia reperfusion injury
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20040202645A1 (en) 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
CA2329274A1 (en) 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
RU2139085C1 (ru) * 1998-06-23 1999-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Средство, стимулирующее репаративные процессы, и способ его применения
JP2002531384A (ja) 1998-11-20 2002-09-24 マウント サイナイ ホスピタル BクラスephrinとPDZ領域との相互作用を変調するペプチド
US6507788B1 (en) 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
US6310041B1 (en) * 1999-03-09 2001-10-30 Fornix Biosciences N.V. Synthetic complementary peptides and ophthalmologic uses thereof
US20030148955A1 (en) 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6379970B1 (en) 1999-04-30 2002-04-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analysis of differential protein expression
RU2157233C1 (ru) * 1999-05-11 2000-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
CA2378480A1 (en) 1999-08-09 2001-02-15 Tripep Ab Pharmaceutical compositions containing tripeptides
GB0005702D0 (en) 2000-03-09 2000-05-03 Alpharma As Method
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
PL356096A1 (pl) 1999-10-15 2004-06-14 Histatek, Llc Kompleks N-formylopeptydowego receptora z czynnikiem modyfikacji ścieżki sygnału kinazy białkowej Goraz sposoby zmiany przekazywania sygnału poprzezstymulację czynnikami prozapalnymi
RU2155063C1 (ru) 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
DE19953339A1 (de) 1999-11-05 2001-05-17 Goldham Pharma Gmbh Secretinfragmente
CA2389429C (en) 1999-11-18 2012-05-29 Victor E. Shashoua Compositions and methods for counteracting effects of reactive oxygen species and free radicals
AU777721B2 (en) * 2000-01-14 2004-10-28 Larson, Richard Peptide inhibitors of LFA-1/ICAM-1 interaction
CA2400187A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
WO2001068113A1 (en) 2000-03-10 2001-09-20 Monsanto Technology Llc Anti-hypertensive peptides
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US6783757B2 (en) * 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6539102B1 (en) 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
EP1217540A1 (en) 2000-11-29 2002-06-26 Lafayette Software Inc. Methods of organizing data and processing queries in a database system, and database system and software product for implementing such method
US20020155106A1 (en) 2000-12-01 2002-10-24 Hammond David J. Method of identifying a ligand for a target molecule
US20060073550A1 (en) * 2001-01-16 2006-04-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002069892A2 (en) * 2001-02-28 2002-09-12 Temple University Of The Commonwealth System Of Higher Education METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6894028B2 (en) 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
JP2004536062A (ja) 2001-05-17 2004-12-02 セレメディックス,インク. 反応性酸素種およびフリーラジカルの効力を中和するためのペプチド化合物
US7368535B2 (en) 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
US20040072246A1 (en) * 2001-09-11 2004-04-15 Roland Martin System and method for identifying t cell and other epitopes and the like
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20080242618A1 (en) 2001-12-21 2008-10-02 Khan Nisar A Stratification
US20080194489A1 (en) 2001-12-21 2008-08-14 Khan Nisar A Treatment of iatrogenic disease
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080242837A1 (en) 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7135286B2 (en) * 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
WO2004016653A2 (en) 2002-08-15 2004-02-26 Leukotech A/S Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase
EP1466612A1 (en) 2003-04-08 2004-10-13 Biotempt B.V. Treatment of inflammation and sepsis with hCG derived peptides
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
US7513755B2 (en) * 2003-07-03 2009-04-07 Vaporless Manufacturing, Inc. Submerged motor and pump assembly
JPWO2005011723A1 (ja) 2003-08-05 2007-10-04 株式会社グリーンペプタイド 造血器腫瘍の予防および/または治療剤
IL157772A (en) * 2003-09-04 2016-06-30 Bmr Solutions Ltd Compounds containing oligopeptide derived from turtle larvae and their use to encourage mammalian hemophysis
WO2005045044A2 (en) * 2003-11-07 2005-05-19 Novartis Ag Use of fibroblast growth factor fragments
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
US20090227505A1 (en) 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
KR101111459B1 (ko) * 2004-03-31 2012-03-13 도판 인사츠 가부시키가이샤 컬러필터 및 이것을 구비한 액정표시장치
EP1838340B1 (en) 2004-12-22 2018-04-04 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー.フェー. 腫瘍の治療
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
DK2120991T3 (da) 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
EP2109054A1 (en) 2008-04-09 2009-10-14 Biotempt B.V. Methods for identifying biologically active peptides and predicting their function

Also Published As

Publication number Publication date
AU2007222178B2 (en) 2013-01-17
CA2645550A1 (en) 2007-09-13
US20090281033A1 (en) 2009-11-12
US20090291901A1 (en) 2009-11-26
US7795226B2 (en) 2010-09-14
EP1864692A1 (en) 2007-12-12
CA2645550C (en) 2014-02-04
KR20090003315A (ko) 2009-01-09
WO2007102735A1 (en) 2007-09-13
ES2399276T3 (es) 2013-03-27
US20110009344A1 (en) 2011-01-13
US8288341B2 (en) 2012-10-16
EP1996292A1 (en) 2008-12-03
EP1996292B1 (en) 2012-10-31
NZ570996A (en) 2012-03-30
AU2007222178A1 (en) 2007-09-13
DK1996292T3 (da) 2013-02-11
US20080027007A1 (en) 2008-01-31
KR101478320B1 (ko) 2015-01-02

Similar Documents

Publication Publication Date Title
PL1996292T3 (pl) Zastosowanie peptydów do kontroli obrażeń popromiennych
PT3424932T (pt) Boronoftalidas para utilização terapêutica
ZA200906210B (en) 3-Imidazolyl-Indoles for the treatment of proliferative diseases
GB0614947D0 (en) Epitope reduction therapy
GB0603041D0 (en) Therapeutic compounds
PT2799427T (pt) Compostos terapêuticos
GB0813087D0 (en) Therapeutic compounds
GB0716532D0 (en) Therapeutic compounds
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
GB0606663D0 (en) Therapeutic compounds
IL200032A0 (en) Medicament for the treatment of endometriosis
IL193910A0 (en) Use of peptides for the control of radiation injury
GB0615809D0 (en) Therapeutic compounds
GB0612971D0 (en) Therapeutic compounds
GB0609121D0 (en) Peptide Therapy
GB0625349D0 (en) Therapeutic compounds
GB0702862D0 (en) Therapeutic compounds
ZA200905300B (en) Medicament for the treatment of endometriosis
GB0808690D0 (en) Therapeutic use
GB0708188D0 (en) Therapeutic compounds
GB0617299D0 (en) Compounds for imaging and therapy
ZA200906937B (en) Formulation for the biological control of insect-pests
GB0708186D0 (en) Therapeutic compounds
GB0613584D0 (en) Therapeutic compounds
GB0602857D0 (en) The treatment of sialorrhoea